Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

安塔瑞斯治疗公司成立，获得1.77亿美元用于开发针对癌症和其他严重疾病的首创精准药物

– Spin-out of Scorpion Therapeutics, led by former Scorpion Therapeutics management team –

– Scorpion Therapeutics分拆，由前Scorpion Therapeutics管理团队领导 –

– Advancing multiple programs across cancer and other serious diseases; plans to advance first new product candidate into the clinic in 2026 –

– 在癌症和其他严重疾病领域推进多个项目；计划于2026年将首个新候选产品推进临床 –

– Series A financing co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from other leading healthcare funds –

- Omega Funds、Atlas Venture、Lightspeed Venture Partners、BVF Partners 和 Cormorant Asset Management 联合领投的 A 轮融资，其他领先的医疗保健基金也参与其中 -

BOSTON, June 10, 2025-- Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors..

波士顿，2025年6月10日——Antares Therapeutics, Inc.（“Antares”），一家致力于开发针对癌症及其他严重疾病的首创精准药物的生物技术公司，今日宣布完成1.77亿美元的A轮融资。本轮融资由Omega Funds、Atlas Venture、Lightspeed Venture Partners、BVF Partners和Cormorant Asset Management共同领投，Vinyanshu Ventures、Abingworth、Invus、Tenmile、Vida Ventures和Willett Advisors参与投资。

Antares is a spin-out of Scorpion Therapeutics, Inc. (“Scorpion”), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company (“Lilly”) in March 2025 for up to $2.5 billion in total consideration. Scorpion was founded in 2020 and, in the subsequent five years, raised a total of $420 million in financing, executed partnerships with multiple pharmaceutical companies, and generated six development candidates, three of which are in clinical testing.

Antares是Scorpion Therapeutics, Inc.（“Scorpion”）的分拆公司，后者于2025年3月将其突变选择性PI3Kα抑制剂项目STX-478出售给Eli Lilly and Company（“Lilly”），总交易额高达25亿美元。Scorpion成立于2020年，在随后的五年内，共筹集了4.2亿美元融资，与多家制药公司达成合作，并生成了六个开发候选药物，其中三个正在进行临床试验。

Antares is led by Scorpion’s former executive leadership team and is advancing a pipeline of small molecule assets developed at Scorpion, including programs in precision oncology and other therapeutic areas, as well as programs initiated through Scorpion’s 2022 transcription factor collaboration with AstraZeneca..

Antares 由 Scorpion 前高管团队领导，正在推进一批在 Scorpion 开发的小分子资产管线，包括精准肿瘤学和其他治疗领域的项目，以及通过 Scorpion 与阿斯利康在2022年转录因子合作启动的项目。

“We took our name from Antares, the brightest star in the Scorpius constellation, and known as ‘the heart of the Scorpion.’ We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares and former Chief Executive Officer of Scorpion.

“我们的名字来源于天蝎座中最亮的星——心宿二，它被称为‘天蝎之心’。我们建立在坚实的基础之上，拥有一支经验丰富的专家团队，他们在新药研发方面具有专长，同时具备自主药物发现能力以及由针对以前无法成药靶点的发现所推动的强大临床前管线，”Antares首席执行官、前Scorpion首席执行官亚当·弗里德曼（Adam Friedman）医学博士、哲学博士说道。

“We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.”.

“我们致力于利用我们的专业知识，针对肿瘤学和其他严重疾病中经过充分验证的、首创的靶点，并继续实施快速进入临床的策略，为有需要的患者带来药物。”

“At Omega, we focus on identifying approaches and working with exceptional teams to deliver impactful products to patients,” said Otello Stampacchia, Ph.D., Founder and Managing Director at Omega Funds. “Antares meets each of these criteria. As one of the founding investors in Scorpion, we have had the opportunity to follow the company’s evolution very closely and have been consistently impressed by the breadth of the team’s capabilities, as well as their scientific rigor and rapid execution.

“在Omega，我们专注于确定方法并与优秀团队合作，为患者提供有影响力的产品，” Omega Funds创始人兼董事总经理Otello Stampacchia博士说道，“Antares符合所有这些标准。作为Scorpion的创始投资者之一，我们有机会紧密关注公司的发展，并始终对其团队能力的广度、科学严谨性以及快速执行力印象深刻。”

I look forward to seeing the company’s vision advance by delivering differentiated, first-in-class products to treat some of the most important unmet medical needs.”.

“我期待看到公司的愿景通过提供差异化、同类首创的产品来治疗一些最重要的未满足医疗需求而取得进展。”

Additionally, Antares announced that Pierre Fabre Laboratories, with whom Scorpion previously partnered to advance two clinical-stage, highly selective next-generation mutant EGFR inhibitors for the treatment of non-small cell lung cancer, has acquired global rights to both programs. Under the terms of the agreement, Pierre Fabre Laboratories will lead the continued clinical development and global commercialization of both programs, and Antares will be eligible to receive regulatory and commercial milestones and tiered royalties..

此外，安塔雷斯宣布，皮埃尔·法布尔实验室与蝎子之前合作推进了两个临床阶段、高度选择性的下一代突变EGFR抑制剂用于治疗非小细胞肺癌，现已获得这两个项目的全球权利。根据协议条款，皮埃尔·法布尔实验室将主导这两个项目的持续临床开发和全球商业化，而安塔雷斯将有资格获得监管和商业里程碑付款以及分级特许权使用费。

Antares’ leadership team

安塔瑞斯的领导团队

Antares is led by the former Scorpion executive team, including leaders with accomplished track records in the biotechnology industry:

安塔瑞斯由前天蝎座高管团队领导，其中包括在生物技术行业有着卓越成就的领导者：

• Adam Friedman, M.D., Ph.D., Chief Executive Officer

• 亚当·弗里德曼，医学博士，哲学博士，首席执行官

• Natasja Brooijmans, Ph.D., Executive Vice President, Discovery Predictive Sciences

• 娜塔莎·布鲁伊曼斯，博士，执行副总裁，发现预测科学

• Mark Chao, M.D., Ph.D., Chief Medical Officer

• 赵马克，医学博士，哲学博士，首席医疗官

• Andrew Fedder, General Counsel

• 安德鲁·费德，总法律顾问

• Angel Guzman-Perez, Ph.D., Executive Vice President, Head of Chemistry

• 安吉尔·古兹曼-佩雷斯，博士，执行副总裁，化学部门主管

• Erica Jackson, Ph.D., Chief Scientific Officer

• 艾丽卡·杰克逊，博士，首席科学官

• Darrin Stuart, Ph.D., Chief Development Officer

• 达林·斯图尔特，博士，首席发展官

• Amanda Valentino, Chief People Officer

• 阿曼达·瓦伦蒂诺，首席人力资源官

The company’s Board of Directors are industry veterans with company-building expertise, as well as experience pioneering breakthrough medicines:

公司的董事会成员是拥有公司建设专业知识的行业资深人士，同时在开创突破性药物方面也具备经验：

• Jeff Albers, J.D., M.B.A., Board Chair at Antares Therapeutics and Venture Partner at Atlas Venture

• Jeff Albers，法学博士，工商管理硕士，Antares Therapeutics董事会主席，Atlas Venture风险合伙人

• Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners

• 朱雪莉，医学博士，哲学博士，光速创投合伙人

• Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School

• Keith Flaherty，医学博士，麻省总医院癌症中心临床研究主任，哈佛医学院教授

• Jean-François Formela, M.D., Partner at Atlas Venture

• Atlas Venture合伙人Jean-François Formela博士

• Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares Therapeutics

• 亚当·弗里德曼，医学博士，哲学博士，安塔雷斯治疗公司首席执行官

• Sir Menelas Pangalos, Ph.D., formerly Executive Vice President of Biopharmaceuticals R&D at AstraZeneca

• 彭格罗斯·梅内拉斯爵士，博士，曾任阿斯利康生物制药研发执行副总裁

“After years of investment into its proprietary drug discovery capabilities, the team at Antares has made notable progress to unlock the therapeutic potential of targets long seen as important – but undruggable – like the large class of transcription factors,” said Sir Menelas Pangalos, Ph.D., independent member of the Antares Board.

“经过多年对其专有药物发现能力的投资，Antares 团队在解锁长期以来被认为重要但不可成药的目标（如转录因子这一大类）的治疗潜力方面取得了显著进展，”Antares 董事会独立成员 Menelas Pangalos 爵士表示。

“I look forward to partnering with the Antares team as they address some of the most complex challenges in science.”.

“我期待与安塔瑞斯团队合作，帮助他们应对科学领域一些最复杂的挑战。”

“Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,” said Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center. 'This team has demonstrated an ability to break through longstanding limits in medicinal chemistry to advance a pipeline of first-in-class assets, aiming to change the treatment landscape for patients.”.

“Antares 将在 Scorpion 开创的基础上继续发展：将尖端的计算和实验化学与生物学同高度专注的临床开发相结合，”麻萨诸塞州总医院癌症中心临床研究主任 Keith Flaherty 医学博士说道。“这支团队展现了突破药物化学长期以来的限制的能力，推动了一系列首创资产的研发，旨在改变患者的治疗前景。”

About Antares Therapeutics

关于安塔瑞斯治疗学

Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares’ most advanced program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development.

安塔瑞斯治疗公司是一家生物技术公司，致力于开发变革性的、首创的精准药物，专注于癌症和其他有重大未满足需求的严重疾病中经过验证的、此前无法成药的靶点。安塔瑞斯最先进的项目预计将于2026年进入临床阶段，同时还有多个其他项目处于临床前开发阶段。

To learn more, visit www.antaresrx.com and follow us on LinkedIn..

要了解更多信息，请访问 www.antaresrx.com 并在 LinkedIn 上关注我们。

Contact:

联系人：

Media:

媒体：

Emily Anderson

艾米丽·安德森

emily.anderson@antaresrx.com

emily.anderson@antaresrx.com

Investor:

投资者：

Danielle Dudgeon

丹妮尔·杜杰农

Precision AQ

精密AQ

danielle.dudgeon@precisionaq.com

丹妮尔·达奇恩@精准AQ.com